Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, valuation, earnings and dividends.
Analyst Recommendations
This is a summary of current ratings for Sunshine Biopharma and Nuvectis Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 0 | 0 | 1 | 0 | 3.00 |
| Nuvectis Pharma | 0 | 0 | 1 | 0 | 3.00 |
Sunshine Biopharma currently has a consensus target price of $15.00, suggesting a potential upside of 597.67%. Nuvectis Pharma has a consensus target price of $11.00, suggesting a potential upside of 50.07%. Given Sunshine Biopharma’s higher probable upside, equities analysts plainly believe Sunshine Biopharma is more favorable than Nuvectis Pharma.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $32.96 million | 0.08 | -$4.51 million | ($150.88) | -0.01 |
| Nuvectis Pharma | N/A | N/A | -$22.26 million | ($1.11) | -6.60 |
Sunshine Biopharma has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 35.8% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Sunshine Biopharma has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Comparatively, Nuvectis Pharma has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.
Profitability
This table compares Sunshine Biopharma and Nuvectis Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -12.82% | -17.89% | -14.25% |
| Nuvectis Pharma | N/A | -155.80% | -104.02% |
Summary
Sunshine Biopharma beats Nuvectis Pharma on 7 of the 11 factors compared between the two stocks.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About Nuvectis Pharma
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
